
About Bellerophon Therapeutics
Bellerophon Therapeutics is a publicly listed company based in Hampton (United States) founded in 2014. Drug-device therapies for pulmonary hypertension are developed. The company has 18 employees. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Aria CV, Adient Medical and Crux Biomedical; 3 of its 3 listed competitors have raised funding.
Company details
Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.
- Headquarters Hampton, United States
- Employees 18
- Stage Public
- SectorsHealthcare
- Website bellerophon.com
- Social LinkedIn
- Net Profit-$19.83 M (USD)-12as on Dec 31, 2022
- EBITDA-$22.38 M (USD)-11as on Dec 31, 2022
- Latest Funding Round$23.44M (USD), Post-IPO
Oct 2017
- InvestorsLinde Group
& 3 more
- Employee Count18
Funding Insights of Bellerophon Therapeutics
- Total Rounds 2
- Last Round Post-IPO — $23.44M
- First Round $23M
(Sep 2017)
- Investors Count 4
All 2 funding rounds of Bellerophon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $23.44M | Post-IPO | – | – | – |
| Sep 2017 | $23M | Post-IPO | – | – |
4 investors in total: 4 institutional.
Investors in Bellerophon Therapeutics
Bellerophon Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Linde Group, Puissance Capital and New Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
New Mountain Capital manages investments in private equity, credit, and net lease strategies. | newmountaincapital.com | |||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Manages diversified investment portfolios across multiple asset classes. | 2015 | puissancecapital.com | New York, United States | |
Industrial, process, and specialty gases are supplied to various sectors. | 1880 | lindeus.com | United States |
Investor details for Bellerophon Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bellerophon Therapeutics
1 people are tracked at Bellerophon Therapeutics (1 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Manfred Hanuschek | Financial Consultant | Team |
Complete people profiles for Bellerophon Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bellerophon Therapeutics
4 dated milestones of Bellerophon Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Bellerophon Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $23.0M.
- Funding Latest funding round, Post-IPO, of $23.4M.
Competitors of Bellerophon Therapeutics
Bellerophon Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aria CV, Adient Medical and Crux Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ariacv.com | 2010 | Saint Paul, United States | $44.98M | 17 | Device for pulmonary hypertension | |
| adientmedical.com | 2012 | Pearland, United States | $19.43M | 6,421 | Bioabsorbable medical devices are developed for pulmonary embolism prevention. | |
| cruxbiomedical.com | 2004 | Menlo Park, United States | $8M | Retrievable vena cava filters are developed to prevent pulmonary emboli. |
Detailed competitors of Bellerophon Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Bellerophon Therapeutics (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bellerophon Therapeutics
Complete news archive for Bellerophon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bellerophon Therapeutics
Bellerophon Therapeutics was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Bellerophon Therapeutics is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.
Bellerophon Therapeutics has 18 employees.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.
Bellerophon Therapeutics's top competitors include Aria CV, Adient Medical and Crux Biomedical.
Bellerophon Therapeutics has 4 investors. Key investors include Linde Group, Puissance Capital, New Mountain Capital, and Venrock Capital Partners.
